Lymphoid tissue engineering: Invoking lymphoid tissue neogenesis in immunotherapy and models of immunity

Seminars in Immunology

Volumn 20, Issue 2, 2008, Pages 137-146

  Irvine, Darrell J ^a   Stachowiak, Agnieszka N ^a   Hori, Yuki ^a  

^a Massachusetts Institute of Technology   (United States)

Author keywords

Homeostatic chemokines; Lymphoid tissue neogenesis; Lymphotoxin; Tertiary lymphoid tissues; Tissue engineering

Indexed keywords

CANCER VACCINE; DNA VACCINE; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; DENDRITIC CELL; GENE EXPRESSION; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG CANCER; LYMPHANGIOGENESIS; LYMPHOCYTE; LYMPHOID ORGAN; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; REVIEW; TISSUE ENGINEERING; TISSUE INDUCTION; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; CANCER VACCINES; CHEMOKINE CCL21; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOID TISSUE; MICE; NEOPLASMS; ORGANOGENESIS; PARACRINE COMMUNICATION; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TUMOR NECROSIS FACTORS;

EID: 40649095267     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2007.10.010     Document Type: Review

References (135)

1. Griffith L.G., and Naughton G. Tissue engineering-current challenges and expanding opportunities. Science 295 (2002) 1009-1014
2. Nerem R.M., and Seliktar D. Vascular tissue engineering. Annu Rev Biomed Eng 3 (2001) 225-243
3. Langer R. Tissue engineering: perspectives, challenges, and future directions. Tissue Eng 13 (2007) 1-2
4. Lutolf M.P., and Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 23 (2005) 47-55
5. De Laporte L., and Shea L.D. Matrices and scaffolds for DNA delivery in tissue engineering. Adv Drug Deliv Rev 59 (2007) 292-307
6. Lutolf M.P., Weber F.E., Schmoekel H.G., Schense J.C., Kohler T., Muller R., et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 21 (2003) 513-518
7. Griffith L.G., and Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7 (2006) 211-224
8. Richardson T.P., Peters M.C., Ennett A.B., and Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 19 (2001) 1029-1034
9. Hollister S.J. Porous scaffold design for tissue engineering. Nat Mater 4 (2005) 518-524
10. Moutos F.T., Freed L.E., and Guilak F. A biomimetic three-dimensional woven composite scaffold for functional tissue engineering of cartilage. Nat Mater 6 (2007) 162-167
11. Brown B., Lindberg K., Reing J., Stolz D.B., and Badylak S.F. The basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng 12 (2006) 519-526
12. Nguyen K.T., and West J.L. Photopolymerizable hydrogels for tissue engineering applications. Biomaterials 23 (2002) 4307-4314
13. Yu X., Botchwey E.A., Levine E.M., Pollack S.R., and Laurencin C.T. Bioreactor-based bone tissue engineering: the influence of dynamic flow on osteoblast phenotypic expression and matrix mineralization. Proc Natl Acad Sci USA 101 (2004) 11203-11208
14. Niklason L.E., Gao J., Abbott W.M., Hirschi K.K., Houser S., Marini R., et al. Functional arteries grown in vitro. Science 284 (1999) 489-493
15. Clark R.A., Ghosh K., and Tonnesen M.G. Tissue engineering for cutaneous wounds. J Invest Dermatol 127 (2007) 1018-1029
16. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature 445 (2007) 874-880
17. Hammond J.S., Beckingham I.J., and Shakesheff K.M. Scaffolds for liver tissue engineering. Exp Rev Med Devices 3 (2006) 21-27
18. Mendelson K., and Schoen F.J. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 34 (2006) 1799-1819
19. Varghese S, Elisseeff JH. Hydrogels for musculoskeletal tissue engineering. In Polymers for Regenerative Medicine. Advances in Polymer Science 2006:95-144.
20. Stern-Straeter J., Riedel F., Bran G., Hormann K., and Goessler U.R. Advances in skeletal muscle tissue engineering. In Vivo 21 (2007) 435-444
21. Lee J.H., Kisiday J., and Grodzinsky A.J. Tissue-engineered versus native cartilage: linkage between cellular mechano-transduction and biomechanical properties. Novartis Found Symp 249 (2003) 52-64 discussion 64-59, 170-174, 239-141
22. Levenberg S., Rouwkema J., Macdonald M., Garfein E.S., Kohane D.S., Darland D.C., et al. Engineering vascularized skeletal muscle tissue. Nat Biotechnol 23 (2005) 879-884
23. Teng Y.D., Lavik E.B., Qu X., Park K.I., Ourednik J., Zurakowski D., et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci USA 99 (2002) 3024-3029
24. Harley B.A., and Yannas I.V. Induced peripheral nerve regeneration using scaffolds. Minerva Biotecnologica 18 (2006) 97-120
25. Willerth S.M., and Sakiyama-Elbert S.E. Approaches to neural tissue engineering using scaffolds for drug delivery. Adv Drug Deliv Rev 59 (2007) 325-338
26. Yu X., and Bellamkonda R.V. Tissue-engineered scaffolds are effective alternatives to autografts for bridging peripheral nerve gaps. Tissue Eng 9 (2003) 421-430
27. Drayton D.L., Liao S., Mounzer R.H., and Ruddle N.H. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 7 (2006) 344-353
28. Mebius R.E. Organogenesis of lymphoid tissues. Nat Rev Immunol 3 (2003) 292-303
29. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
30. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23 (2005) 787-819
31. Cyster J.G. Lymphoid organ development and cell migration. Immunol Rev 195 (2003) 5-14
32. Nishikawa S., Honda K., Vieira P., and Yoshida H. Organogenesis of peripheral lymphoid organs. Immunol Rev 195 (2003) 72-80
33. Cupedo T., Lund F.E., Ngo V.N., Randall T.D., Jansen W., Greuter M.J., et al. Initiation of cellular organization in lymph nodes is regulated by non-B cell-derived signals and is not dependent on CXC chemokine ligand 13. J Immunol 173 (2004) 4889-4896
34. Ohl L., Henning G., Krautwald S., Lipp M., Hardtke S., Bernhardt G., et al. Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J Exp Med 197 (2003) 1199-1204
35. Cupedo T., Jansen W., Kraal G., and Mebius R.E. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 21 (2004) 655-667
36. Yoshida H., Naito A., Inoue J., Satoh M., Santee-Cooper S.M., Ware C.F., et al. Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches. Immunity 17 (2002) 823-833
37. Ngo V.N., Korner H., Gunn M.D., Schmidt K.N., Riminton D.S., Cooper M.D., et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 189 (1999) 403-412
38. Cuff C.A., Schwartz J., Bergman C.M., Russell K.S., Bender J.R., and Ruddle N.H. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 161 (1998) 6853-6860
39. Hemmerich S., Bistrup A., Singer M.S., van Zante A., Lee J.K., Tsay D., et al. Sulfation of l-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes. Immunity 15 (2001) 237-247
40. von Andrian U.H., and Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3 (2003) 867-878
41. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23 (2005) 127-159
42. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 (1999) 23-33
43. Gunn M.D., Kyuwa S., Tam C., Kakiuchi T., Matsuzawa A., Williams L.T., et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189 (1999) 451-460
44. Gunn M.D., Ngo V.N., Ansel K.M., Ekland E.H., Cyster J.G., and Williams L.T. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391 (1998) 799-803
45. Luther S.A., Tang H.L., Hyman P.L., Farr A.G., and Cyster J.G. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci USA 97 (2000) 12694-12699
46. Muller G., Hopken U.E., and Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev 195 (2003) 117-135
47. Willimann K., Legler D.F., Loetscher M., Roos R.S., Delgado M.B., Clark-Lewis I., et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28 (1998) 2025-2034
48. Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Forster R., Sedgwick J.D., et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406 (2000) 309-314
49. Forster R., Mattis A.E., Kremmer E., Wolf E., Brem G., and Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87 (1996) 1037-1047
50. Banks T.A., Rouse B.T., Kerley M.K., Blair P.J., Godfrey V.L., Kuklin N.A., et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 155 (1995) 1685-1693
51. De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264 (1994) 703-707
52. Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., and Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6 (1997) 491-500
53. Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., et al. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc Natl Acad Sci USA 94 (1997) 9302-9307
54. Futterer A., Mink K., Luz A., Kosco-Vilbois M.H., and Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9 (1998) 59-70
55. Kuprash D.V., Alimzhanov M.B., Tumanov A.V., Anderson A.O., Pfeffer K., and Nedospasov S.A. TNF and lymphotoxin beta cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes. J Immunol 163 (1999) 6575-6580
56. Picarella D.E., Kratz A., Li C.B., Ruddle N.H., and Flavell R.A. Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas. Proc Natl Acad Sci USA 89 (1992) 10036-10040
57. Picarella D.E., Kratz A., Li C.B., Ruddle N.H., and Flavell R.A. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. J Immunol 150 (1993) 4136-4150
58. Kratz A., Campos-Neto A., Hanson M.S., and Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183 (1996) 1461-1472
59. Drayton D.L., Ying X., Lee J., Lesslauer W., and Ruddle N.H. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med 197 (2003) 1153-1163
60. Hjelmstrom P., Fjell J., Nakagawa T., Sacca R., Cuff C.A., and Ruddle N.H. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 156 (2000) 1133-1138
61. Luther S.A., Lopez T., Bai W., Hanahan D., and Cyster J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12 (2000) 471-481
62. Fan L., Reilly C.R., Luo Y., Dorf M.E., and Lo D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol 164 (2000) 3955-3959
63. Luther S.A., Bidgol A., Hargreaves D.C., Schmidt A., Xu Y., Paniyadi J., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 169 (2002) 424-433
64. Chen S.C., Vassileva G., Kinsley D., Holzmann S., Manfra D., Wiekowski M.T., et al. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol 168 (2002) 1001-1008
65. Martin A.P., Coronel E.C., Sano G., Chen S.C., Vassileva G., Canasto-Chibuque C., et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol 173 (2004) 4791-4798
66. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., and Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 195 (2002) 1613-1624
67. Wang J., Foster A., Chin R., Yu P., Sun Y., Wang Y., et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol 32 (2002) 1969-1979
68. Harmsen A., Kusser K., Hartson L., Tighe M., Sunshine M.J., Sedgwick J.D., et al. Cutting edge: organogenesis of nasal-associated lymphoid tissue (NALT) occurs independently of lymphotoxin-alpha (LT alpha) and retinoic acid receptor-related orphan receptor-gamma, but the organization of NALT is LT alpha dependent. J Immunol 168 (2002) 986-990
69. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999) 2412-2424
70. Kim D., Mebius R.E., MacMicking J.D., Jung S., Cupedo T., Castellanos Y., et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192 (2000) 1467-1478
71. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
72. Rich B.E., Campos-Torres J., Tepper R.I., Moreadith R.W., and Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 177 (1993) 305-316
73. Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., Hartson L., Sprague F., Goodrich S., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 10 (2004) 927-934
74. Mazzucchelli L., Blaser A., Kappeler A., Scharli P., Laissue J.A., Baggiolini M., et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 104 (1999) R49-R54
75. Stolte M., and Eidt S. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori?. J Clin Pathol 42 (1989) 1269-1271
76. Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol 69 (2001) 331-339
77. Katakai T., Hara T., Sugai M., Gonda H., and Shimizu A. Th1-biased tertiary lymphoid tissue supported by CXC chemokine ligand 13-producing stromal network in chronic lesions of autoimmune gastritis. J Immunol 171 (2003) 4359-4368
78. Katakai T., Nomura T., Gonda H., Sugai M., Agata Y., Nishio A., et al. Spontaneous large-scale lymphoid neogenesis and balanced autoimmunity versus tolerance in the stomach of H+/K+-ATPase-reactive TCR transgenic mouse. J Immunol 177 (2006) 7858-7867
79. Takemura S., Braun A., Crowson C., Kurtin P.J., Cofield R.H., O'Fallon W.M., et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167 (2001) 1072-1080
80. Thaunat O., Field A.C., Dai J., Louedec L., Patey N., Bloch M.F., et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 102 (2005) 14723-14728
81. Baddoura F.K., Nasr I.W., Wrobel B., Li Q., Ruddle N.H., and Lakkis F.G. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 5 (2005) 510-516
82. Heikenwalder M., Zeller N., Seeger H., Prinz M., Klohn P.C., Schwarz P., et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 307 (2005) 1107-1110
83. Schroder A.E., Greiner A., Seyfert C., and Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 93 (1996) 221-225
84. Stott D.I., Hiepe F., Hummel M., Steinhauser G., and Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 102 (1998) 938-946
85. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., and Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11 (2005) 335-339
86. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
87. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
88. Li Q., Pan P.Y., Gu P., Xu D., and Chen S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64 (2004) 1130-1139
89. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95 (1998) 1178-1183
90. Gastman B.R., Atarshi Y., Reichert T.E., Saito T., Balkir L., Rabinowich H., et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 (1999) 5356-5364
91. Chappell D.B., and Restifo N.P. T cell-tumor cell: a fatal interaction?. Cancer Immunol Immunother 47 (1998) 65-71
92. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., and Hengartner H. Zinkernagel RM: immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96 (1999) 2233-2238
93. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
94. Yu P., Rowley D.A., Fu Y.X., and Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18 (2006) 226-231
95. Toka F.N., Gierynska M., and Rouse B.T. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Virol 77 (2003) 12742-12752
96. Flesch I.E., Stober D., Schirmbeck R., and Reimann J. Monocyte inflammatory protein-1 alpha facilitates priming of CD8(+) T cell responses to exogenous viral antigen. Int Immunol 12 (2000) 1365-1370
97. Zhao X., Jain S., Benjamin Larman H., Gonzalez S., and Irvine D.J. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 26 (2005) 5048-5063
98. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114 (2004) 1334-1342
99. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17 (1999) 253-258
100. Song R., Liu S., and Leong K.W. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther 15 (2007) 1007-1015
101. Xin K.Q., Lu Y., Hamajima K., Fukushima J., Yang J., Inamura K., et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 92 (1999) 90-96
102. Gough M., Crittenden M., Thanarajasingam U., Sanchez-Perez L., Thompson J., Jevremovic D., et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 174 (2005) 5766-5773
103. Arenberg D.A., Zlotnick A., Strom S.R., Burdick M.D., and Strieter R.M. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother 49 (2001) 587-592
104. Stachowiak A.N., Wang Y., Huang Y.C., and Irvine D.J. Homeostatic lymphoid chemokines synergize with adhesion ligands to trigger T and B lymphocyte chemokinesis. J Immunol 177 (2006) 2340-2348
105. Flanagan K., Moroziewicz D., Kwak H., Horig H., and Kaufman H.L. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol 231 (2004) 75-84
106. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164 (2000) 4558-4563
107. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61 (2001) 2062-2070
108. Hillinger S., Yang S.C., Zhu L., Huang M., Duckett R., Atianzar K., et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 171 (2003) 6457-6465
109. Vicari A.P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., and Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165 (2000) 1992-2000
110. Novak L., Igoucheva O., Cho S., and Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 6 (2007) 1755-1764
111. Braun S.E., Chen K., Foster R.G., Kim C.H., Hromas R., Kaplan M.H., et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164 (2000) 4025-4031
112. Yang S.C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10 (2004) 2891-2901
113. Kirk C.J., Hartigan-O'Connor D., and Mule J.J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61 (2001) 8794-8802
114. Sharma S., Yang S.C., Hillinger S., Zhu L.X., Huang M., Batra R.K., et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2 (2003) 22
115. Schrama D., thor Straten P., Fischer W.H., McLellan A.D., Brocker E.B., Reisfeld R.A., et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14 (2001) 111-121
116. Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 102 (1998) 1142-1151
117. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273 (1998) 27548-27556
118. Tamada K., Shimozaki K., Chapoval A.I., Zhu G., Sica G., Flies D., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 6 (2000) 283-289
119. Lejeune F.J., Lienard D., Leyvraz S., and Mirimanoff R.O. Regional therapy of melanoma. Eur J Cancer 29A (1993) 606-612
120. Reisfeld R.A., Gillies S.D., Mendelsohn J., Varki N.M., and Becker J.C. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 56 (1996) 1707-1712
121. Gillies S.D., Young D., Lo K.M., Foley S.F., and Reisfeld R.A. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10 (1991) 347-356
122. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
123. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004) 141-149
124. Hisada M., Yoshimoto T., Kamiya S., Magami Y., Miyaji H., Yoneto T., et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 11 (2004) 280-288
125. Hutmacher D.W. Scaffold design and fabrication technologies for engineering tissues--state of the art and future perspectives. J Biomater Sci Polym Ed 12 (2001) 107-124
126. Luo Y., and Shoichet M.S. A photolabile hydrogel for guided three-dimensional cell growth and migration. Nat Mater 3 (2004) 249-253
127. Frenkel S.R., and Di Cesare P.E. Scaffolds for articular cartilage repair. Ann Biomed Eng 32 (2004) 26-34
128. Lee K.Y., Peters M.C., Anderson K.W., and Mooney D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 408 (2000) 998-1000
129. Hughes V. Therapy on trial. Nat Med 13 (2007) 1008-1009
130. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317 (2007) 477
131. Stachowiak A.N. Inverse opal hydrogel scaffolds as lymphoid microenvironments for the study of immune cell migration and immunotherapy (2007), Massachusetts Institute of Technology, Cambridge
132. Stachowiak A., Bershteyn A., and Irvine D.J. Bioactive hydrogels with an ordered cellular structure combine interconnected macroporosity and robust mechanical properties. Adv Mater 17 (2005) 399-403
133. Stachowiak AN, Irvine DJ. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J Biomed Mater Res A; in press [Epub ahead of print].
134. Suematsu S., and Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat Biotechnol 22 (2004) 1539-1545
135. Okamoto N., Chihara R., Shimizu C., Nishimoto S., and Watanabe T. Artificial lymph nodes induce potent secondary immune responses in naive and immunodeficient mice. J Clin Invest 117 (2007) 997-1007